^
Association details:
| Biomarker: | NTRK2 positive |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer
Published date:
04/12/2021
Excerpt:
...NTRK+ metastatic thyroid cancer patients (including both anaplastic and differentiated thyroid cancer patients) from the larotrectinib...Larotrectinib is estimated to be superior to sorafenib and lenvatinib in eligible advanced thyroid cancer patients.
